Local production of complement proteins in rheumatoid arthritis synovium

Arthritis and Rheumatism

Volumn 46, Issue 4, 2002, Pages 934-945

  Neumann, Elena ^a   Barnum, Scott R ^b   Tarner, Ingo H ^a   Echols, Josh ^b   Fleck, Martin ^a   Judex, Martin ^a   Kullmann, Frank ^a   Mountz, John D ^b   Schölmerich, Jürgen ^a   Gay, Steffen ^c   Müller Ladner, Ulf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT RECEPTOR; CYTOKINE ANTIBODY; MESSENGER RNA; PROTEIN P55;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COMPLEMENT FACTOR; COMPLEMENT SYSTEM; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; FEMALE; GENE OVEREXPRESSION; GENE TRANSFER; HUMAN; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; SCID MOUSE; SYNOVIAL FLUID LEVEL; SYNOVIUM;

AGED; ANIMALS; ANTIGENS, CD; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR B; COMPLEMENT MEMBRANE ATTACK COMPLEX; COMPLEMENT SYSTEM PROTEINS; FEMALE; FIBROBLASTS; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; MALE; MEMBRANE PROTEINS; MICE; MICE, SCID; MIDDLE AGED; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, COMPLEMENT; RNA, MESSENGER; SYNOVIAL MEMBRANE;

EID: 0036226744     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.10183     Document Type: Article

References (50)

1. T cells in arthritis
2. Cell-cell interactions in synovitis: Interactions between T cells and B cells in rheumatoid arthritis
3. Central nervous system-targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis
4. The complement system: Pathophysiology and clinical relevance
5. Complement activation following oxidative stress
6. The complement system: An overview
7. Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects
8. Rheumatoid arthritis: Biosynthesis of complement proteins by synovial tissues
9. Complement activation in rheumatoid arthritis evaluated by C3dg and the terminal complement complex
10. Relation between synovial fluid C3 degradation products and local joint inflammation in rheumatoid arthritis, osteoarthritis, and crystal associated arthropathy
11. Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: Role of C5a in the acute inflammatory phase
12. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis
13. C3 activation products, C3 containing immune complexes, the terminal complement complex and native C9 in patients with rheumatoid arthritis
14. Gene expression (collagenase, tissue inhibitor of metalloproteinases complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium: Quantitative analysis and effect of intraarticular corticosteroids
15. Terminal complement complex in synovial tissue from patients affected by rheumatoid arthritis, osteoarthritis and acute joint trauma
16. Synthesis of complement components by synovial membrane
17. Expression of the components and regulatory proteins of the alternative complement pathway and the membrane attack complex in normal and diseased synovium
18. Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid
19. Complement in acute and chronic arthritides: Assessment of C3c, C9, and protectin (CD59) in synovial membrane
20. Mononuclear phagocytes have the potential to synthesize the complete functional complement system
21. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
22. Cellular specificity of murine renal C3 expression in two models of inflammation
23. The mouse anaphylatoxin C3a receptor: Molecular cloning, genomic organization, and functional expression
24. TNF-α-mediated expression of the receptor for anaphylatoxin C5a on neurons in experimental Listeria meningoencephalitis
25. Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells
26. Improved accuracy in diagnostic immunohistochemistry, lectin histochemistry and in situ hybridization using a gold-labeled horseradish peroxidase antibody and silver intensification
27. Transforming growth factor-β1 inhibits inflammatory cytokine-induced C3 gene expression in astrocytes
28. Radioassays for quantitation of intact complement proteins C2 and B in human serum
29. Gene transfer of cytokine inhibitors into human synovial fibroblasts in the SCID mouse model
30. "Inverse wrap": An improved implantation technique for virus-transduced synovial fibroblasts in the SCID-mouse model for RA
31. Circulating complement breakdown products in patients with rheumatoid arthritis: Correlation between plasma C3d, circulating immune complexes, and clinical activity
32. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity
33. Assessment of the potential pathogenicity of type II collagen autoantibodies in patients with rheumatoid arthritis: Evidence of restricted IgG3 subclass expression and activation of complement C5 to C5a
34. Activation of the classical pathway of complement by rheumatoid factors: Assessment by radioimmunoassay for C4
35. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis
36. Stimulation of rheumatoid synovial cells by non-lethal complement membrane attack
37. Human rheumatoid synovial cell stimulation by the membrane attack complex and other pore-forming toxins in vitro: The role of calcium in cell activation
38. Rheumatoid arthritis and p53: How oxidative stress might alter the course of inflammatory diseases
39. Interaction of the terminal complement components C5b-9 with synovial fibroblasts: Binding to the membrane surface leads to increased levels in collagenase-specific mRNA
40. Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: Immunohistochemical studies with an active form specific antibody
41. Immunolocalization of complement C1s and matrix metalloproteinase 9 (92kDa gelatinase/type IV collagenase) in the primary ossification center of the human femur
42. Change of complement C1s synthesis during development of hamster cartilage
43. Complement C1s, a classical enzyme with novel functions at the endochondral ossification center: Immunohistochemical staining of activated C1s with a neoantigen-specific antibody
44. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease
45. SWR mice are resistant to collagen-induced arthritis but produce potentially arthritogenic antibodies
46. The role of C5 and T-cell receptor Vb genes in susceptibility to collagen-induced arthritis
47. Genetic control of susceptibility to collagen-induced arthritis in T cell receptor β-chain transgenic mice
48. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis
49. Local therapy with soluble complement receptor 1 (sCR1) suppresses inflammation in rat mono-articular arthritis
50. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis